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HIGHLIGHTS 
1. Mesenchymal niche cells induce genotoxic stress in HSPCs in a mouse model of SDS 
2. p53-S100A8/9-TLR4 inflammatory signaling is identified as the underlying mechanism 
3. Mesenchymal S100A8/9 predicts leukemic evolution and disease outcome in MDS  
 
SUMMARY 
Mesenchymal niche cells may drive tissue failure and malignant transformation in the hematopoietic 
system but the molecular mechanisms and their relevance to human disease remain poorly defined. 
Here, we show that perturbation of mesenchymal cells in a mouse model of the preleukemic disorder 
Shwachman-Diamond syndrome induces mitochondrial dysfunction, oxidative stress and activation 
of DNA damage responses in hematopoietic stem and progenitor cells. Massive parallel RNA 
sequencing of highly purified mesenchymal cells in the mouse model and a range of human 
preleukemic syndromes identified p53-S100A8/9-TLR inflammatory signaling as a common driving 
mechanism of genotoxic stress.  
Transcriptional activation of this signaling axis in the mesenchymal niche predicted leukemic 
evolution and progression-free survival in myelodysplastic syndrome, the principal leukemia 
predisposition syndrome. Collectively, our findings reveal a concept of mesenchymal niche-induced 
genotoxic stress in heterotypic stem and progenitor cells through inflammatory signaling as an 
actionable determinant of disease outcome in human preleukemia. 
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INTRODUCTION 
Genotoxic stress results in the accumulation of DNA lesions in hematopoietic stem and progenitor 
cells (HSPCs) over the lifespan of an organism, contributing to tissue failure and malignant 
transformation (Jaiswal et al., 2014; Rossi et al., 2007). The pathophysiological insults underlying 
genomic stress in HSPCs, however, remain incompletely understood. Perturbed signaling from their 
surrounding microenvironment may be implicated, but this has not been experimentally defined.  
Components of the bone marrow microenvironment have emerged as key regulators of normal and 
malignant hematopoiesis (Arranz et al., 2014; Hanoun et al., 2014; Medyouf et al., 2014; Schepers et 
al., 2015; Walkley et al., 2007). We, and others, have shown that primary alterations of the 
mesenchymal niche can induce myelodysplasia and promote the emergence of acute myeloid 
leukemia (AML) with cytogenetic abnormalities in HSPCs (Kode et al., 2014; Raaijmakers et al., 
2010), thus introducing a concept of niche-driven oncogenesis in the hematopoietic system.  
To provide insights into the mechanisms that underlie this concept, as well as their relevance for 
human disease, we modeled the human leukemia predisposition disorder Shwachman-Diamond 
syndrome (SDS), caused by constitutive homozygous or compound heterozygous loss of function 
mutations in the SBDS gene, required for ribosome biogenesis (Boocock et al., 2003; Finch et al., 
2011). SDS is characterized by skeletal defects in conjunction with a striking propensity to develop 
myelodysplastic syndrome (MDS) and AML at a young age, with a cumulative probability of >30% 
at the age of 30 years and a median onset at 18 years (Alter, 2007; Donadieu et al., 2012). 
Hematopoietic cell intrinsic loss of Sbds does not result in MDS or leukemia (Rawls et al., 2007; 
Zambetti et al., 2015), supporting the notion that cell-extrinsic factors contribute to malignant 
transformation. Deletion of Sbds from mesenchymal cells expressing the mesenchymal progenitor 
marker osterix (Sp7) in the bone marrow induced apoptosis in HSPCs and myelodysplasia, but the 
molecular mechanisms driving these observations and their relevance for human disease remained to 
be defined (Raaijmakers et al., 2010). 
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Here, we identify the endogenous damage-associated molecular pattern (DAMP) molecules S100A8 
and S100A9, secreted from mesenchymal niche cells, as drivers of mitochondrial dysfunction, 
oxidative stress and DNA damage response (DDR) activation in HSPCs, with clinical relevance to 
the pathogenesis and prognosis of human bone marrow failure and leukemia predisposition 
syndromes. 
RESULTS 
Deletion of Sbds from mesenchymal progenitor cells (MPCs) recapitulates skeletal 
abnormalities of human SDS 
SDS is characterized by bone abnormalities including low-turnover osteoporosis with reduced 
trabecular bone volume, low numbers of osteoblasts, and reduced amount of osteoid, leading to 
increased risk of fractures (Toiviainen-Salo et al., 2007). The cellular subsets driving these 
abnormalities and the underlying molecular mechanisms have remained largely undefined. We have 
previously shown that Cre-mediated deletion of Sbds from osterix+ MPCs (Sbdsf/f Osxcre/+ mice, 
hereafter OCSf/f or mutants) disrupts the architecture of the marrow and cortical bone (Raaijmakers 
et al., 2010). Here, we first sought to better define the skeletal defects in these mice and their relevance 
to human disease. 
OCSf/f mice presented growth retardation and reduced femur length compared to control Sbdsf/+ 
Osxcre/+ (OCSf/+) mice (Figure 1A and 1B) as observed in human patients (Aggett et al., 1980; 
Ginzberg et al., 1999). The runted phenotype was associated with a significantly limited lifespan, 
with lethality observed after the age of 4 weeks. Analyses were therefore performed in three week-
old mice. The femur trabecular area was profoundly reduced in OCSf/f mice, with decreased bone 
volume, low number of trabeculae, increased trabecular spacing and reduced numbers of osteoblasts 
compared to controls (Figure 1C-1G, and 1I). The cortical bone of OCS mutants was also affected, 
as indicated by low bone mineral density values (Figure 1C-1D and 1H), attenuating the mechanical 
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properties of the bone, which was found less resistant to fracture in three-point bending test (Figure 
1J). A tendency for reduced stiffness in the long bones was also observed (Figure 1K). Taken together, 
the structural and mechanical defects indicate that Sbds deficiency in MPCs causes osteoporosis with 
a propensity for fracturing, in line with observations in SDS patients (Ginzberg et al., 1999; Mäkitie 
et al., 2004; Toiviainen-Salo et al., 2007). Impaired osteogenesis did not reflect a contraction of the 
bone progenitor cell pool as shown by frequency of CFU-F and Osx::GFP+ cells (Figure S1A and 
S1B), but rather impairment of terminal osteogenic differentiation as suggested by transcriptional 
profiling of prospectively isolated osterix-expressing (GFP+) cells (Figure S1C). Transcriptional data 
confirmed deregulated expression of genes related to ribosomal biogenesis and translation (Figure 
S1D and S1E), in line with the established role of Sbds in ribosome biogenesis. Collectively, this data 
supports a view in which bone abnormalities in SDS are caused by deficiency of Sbds in MPCs, which 
attenuates terminal differentiation towards matrix-depositing osteoblastic cells with a compensatory 
increase in the most primitive mesenchymal compartment.  
Sbds deficiency in the hematopoietic niche induces mitochondrial dysfunction, oxidative stress 
and activation of the DNA damage response in HSPCs 
Having established that the OCS mice represent a bona fide model for bone abnormalities in human 
disease, we next investigated the hematopoietic consequences of these environmental alterations. 
HSPC number was unaltered in OCS mice (Figure S2A-S2C) and HSPCs displayed global 
preservation of their transcriptional landscape after exposure to the Sbds-deficient environment 
(Figure S2D-S2F). Transcriptional network analysis, however, revealed significant overlap with 
signatures previously defined as predicting leukemic evolution of human CD34+ cells (Li et al., 2011), 
including pathways signaling mitochondrial abnormalities (Figure 2A; Table S1). Mitochondrial 
dysfunction was confirmed by measuring the mitochondrial membrane potential (Δψ), indicating 
hyperpolarization of the mitochondria (Figure 2B and 2C). Mitochondrial hyperpolarization can 
result in reverse electron transfer, leading to the production of superoxide radicals, which can be 
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further converted into other reactive oxygen species (ROS) (Murphy, 2009). In line with this, a 
marked increase in intracellular ROS levels was found in OCS mutant HSPCs (Figure 2D), more 
specifically superoxide radicals derived from mitochondria as shown by dihydroethidium (DHE) 
staining (Figure S2G) (Owusu-Ansah et al., 2008; Stowe et al, 2009). ROS can undermine the 
genomic integrity of HSPCs by inducing DNA damage (Ito et al., 2006; Walter et al., 2015; Yahata 
et al., 2011), to which normal HSPCs react by activating the DDR and DNA repair pathways (Rossi 
et al., 2007). Indeed, HSPCs (LKS-SLAM) cells from OCSf/f mice displayed accumulation of Ser139-
phosphorylated H2AX histone (γH2AX), which forms at the sites of DNA damage (Figure 2E; Figure 
S2H). Treatment of OCS mutant animals with the ROS scavenger N-acetylcysteine (NAC) resulted 
in partial reduction in the accumulation of gH2AX (Figure S2I and S2J). Congruent with genotoxic 
effects of the mutant microenvironment, HSPCs displayed transcriptional modulation of DDR and 
DNA repair pathways (Table S2), including  nucleotide excision repair programs, associated with 
ROS-induced lesions (Curtin, 2012) and signatures related to the master regulator of DDR and cell 
checkpoint activation ataxia telangiectasia and Rad3-related (ATR). Activation of the G1-S cell cycle 
checkpoint, resulting in cell cycle arrest, was suggested by depletion of S-phase transcriptional 
signatures (Figure 2F; Table S1), in vivo BrdU/Ki67 labeling (Figure 2G and 2H; Figure S2K) and 
downregulation of the Myc pathway, a critical regulator for this restriction point and the coordination 
of S–G2–M progression (Figure 2I; Table S3). Apoptosis of mutant HSPCs, as an alternative outcome 
of checkpoint activation, was earlier demonstrated (Raaijmakers et al., 2010). Together, the data 
indicate that the Sbds-deficient environment induces mitochondrial dysfunction, oxidative stress, 
DNA damage and genotoxic stress in HSPCs leading to activation of DDR pathways and G1-S 
checkpoint activation, reminiscent of a model in which mitochondrial dysfunction underlies an 
escalating cycle of increased ROS and genotoxic damage (Sahin and Depinho, 2010).  
Short term exposure to the genotoxic environment did not attenuate HSPC function in DNA repair 
proficient cells, as demonstrated by competitive transplantation experiments (Figure S3A-S3C), 
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suggesting efficient DNA-repair or elimination of functionally impaired HSPCs by the DDR-driven 
apoptosis and cell cycle arrest. Congruent with this notion, alkaline comet assays on sorted HSPCs 
failed to demonstrate structural DNA damage (Figure S3D and S3E). 
Activation of the p53 pathway drives bone abnormalities and genotoxic stress in OCS mice 
Next, we sought to define the molecular programs underlying the bone and hematopoietic alterations 
in OCS mice. A proposed common molecular mechanism for the pathogenesis of ribosomopathies 
involves activation of the p53 tumor suppressor pathway (Raiser et al., 2014). The p53 protein was 
overexpressed in GFP+ MPCs in OCS mutants, with activation of downstream transcriptional 
pathways and upregulation of canonical targets (Figure 3A-3C). To assess the pathophysiological role 
of p53 activation in MPCs, we intercrossed OCS with Trp53-floxed mice (Marino et al., 2000), 
generating a double conditional knock-out model where the deletion of p53 is localized in the Sbds-
deleted stromal compartment (Sbdsf/f Trp53f/f Osxcre/+ mice; hence OCSf/f p53Δ) (Figure 3D). Genetic 
recombination of the Trp53 locus was detected only in bone cells-containing samples, demonstrating 
the tissue specificity of p53 deletion in this model (Figure 3E). Genetic deletion of p53 from Sbds-
deficient MPCs rescued the osteoporotic phenotype (Figure 3F-3J), but not cortical bone 
mineralization (Figure 3K), while it had only modest effects on bone mass in OCS control mice 
(Figure S4), in line with earlier observations (Wang et al., 2006). Rescue of the skeletal phenotype 
was linked to amelioration of genotoxic stress in HSPCs as demonstrated by a reduction of superoxide 
radicals derived from mitochondria and DNA damage (Figure 3L and 3M). 
Identification of the damage-associated molecular pattern genes S100A8 and S100A9 as 
candidate niche factors driving genotoxic stress in human leukemia predisposition syndromes  
To identify human disease-relevant niche factors, downstream of p53 activation, driving genomic 
stress in HSPCs, we compared the transcriptomes of GFP+ MPCs from OCS mice to those from 
prospectively FACS-isolated mesenchymal CD271+ niche cells (Tormin et al., 2011) from human 
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SDS patients (Figure 4A; Table S4). The mesenchymal nature of CD271+ cells was confirmed by 
CFU-F capacity and differential expression of mesenchymal, osteolineage and HSPC-regulatory 
genes (Chen et al, 2016). RNA sequencing showed the presence of SBDS mutations (Figure 4B; 
Figure S5; Table S4) associated with reduced SBDS expression (Figure 4C), confirming molecular 
aspects of SDS in previous studies (Finch et al., 2011; Woloszynek et al., 2004). Identical 
transcriptional signatures of disrupted ribosome biogenesis and translation were found in human 
niche cells (Figure 4D) and in GFP+ cells from OCS mice (Figure S1E), confirming faithful 
recapitulation of human molecular disease characteristics in the mouse model. Forty genes were 
differentially expressed both in the mouse model and human SDS, 25 of which were overexpressed, 
with a remarkable abundance of genes encoding proteins implicated in inflammation and innate 
immunity (Figure 4E).  
To further delineate candidate genes driving genomic stress and leukemic evolution from this gene 
set, we performed whole transcriptome sequencing of CD271+ cells in two related human bone 
marrow failure and leukemia predisposition disorders: (1) low-risk MDS, the principal human 
preleukemic disorder in which cell cycle exit (senescence), accumulation of ROS, DNA damage and 
apoptosis have been described (Head et al., 2011; Peddie et al., 1997; Xiao et al., 2013), reminiscent 
of HSPC phenotypes in OCS mice, and (2) DBA, like SDS, a ribosomopathy characterized by bone 
marrow failure, but with a much lower propensity to evolve into AML (<1% with longer latency than 
observed in SDS and MDS) (Vlachos et al., 2012) (Table S4). We reasoned that genes specifically 
overexpressed in mesenchymal niche cells from disorders with as strong propensity for leukemic 
evolution (SDS and MDS) might represent strong candidate drivers of genotoxic stress. Eleven such 
genes were found (Figure 4F), among which the damage-associated molecular pattern (DAMP) 
S100A8 and S100A9, significantly (P<0.05) differentially expressed in GFP+ cells from OCS mutant 
mice (Figure 4E-4G) and a bona fide downstream transcriptional target of p53 (Li et al., 2009). Ex 
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vivo shRNA experiments confirmed that upregulation of both p53 and S100A8/9 are direct, cell-
intrinsic consequences of Sbds downregulation in mesenchymal precursor (OP9) cells (Figure S6A). 
Niche-derived S100A8/9 induces genotoxic stress in murine and human HSPCs  
S100A8 and S100A9 belong to a subclass of proinflammatory molecules referred to as DAMP or 
alarmins. DAMPs are endogenous danger signals that are passively released or actively secreted in 
the microenvironment after cell death, damage or stress and bind pattern recognition receptors (PRR) 
to regulate inflammation and tissue repair (Srikrishna and Freeze, 2009). S100A8 and S100A9 
proteins were overexpressed in mouse Sbds-deficient MPCs (Figure 5A and 5B) and increased plasma 
concentration of S100A8/9 indicated secretion of the heterodimer (Figure 5C). Its canonical receptor 
TLR4 (Vogl et al., 2007) is expressed in murine HSPCs (Figure S6B) and the canonical downstream 
signaling NF-κB and MAPK pathways were activated in HSPCs from OCSf/f mice (Figure S6C).  
Exposure of HSPCs (LKS) cells to recombinant murine S100A8/9 resulted in increased DNA damage 
(number of γH2AX and 53BP1 foci) (Figure 5D; Figure S6D), which was replication-independent 
(Figure 5E), and apoptosis (Figure 5F), associated with activation of TLR signaling (Figure 5G; Table 
S5), recapitulating the in vivo HSPC phenotype (Raaijmakers et al., 2010). In vivo, blockage of TLR4 
by neutralizing antibodies resulted in a reduction of γH2AX foci in LKS cells from OCSf/f mice 
(Figure 5H). 
To provide formal experimental support for the view that S100A8/9 production by ancillary cells in 
the bone marrow microenvironment is sufficient to drive genotoxic stress in HSPCs in a paracrine 
manner, we next transplanted CD45.1+ wild type hematopoietic cells into S100A9-GFP transgenic 
(S100A9Tg) mice, overexpressing both S100A8 and S100A9 under control of the MHC class I H2K 
promoter (Cheng et al., 2008) (Figure 6A). S100A8/9 (GFP) was expressed in a mesenchymal (CD45- 
CD31- Ter119- CD51+ Sca1-) niche population, previously shown to contain the Osterix-expressing 
cells (Schepers et al, 2013) (Figure 6B and 6C). The S100A8/9+ microenvironment induced 
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accumulation of superoxide radicals (DHE) and DNA-damage (γH2AX) in wild type (CD45.1+) 
HSPCs (Figure 6D-6F), in particular in immunophenotypic HSCs, indicating that secretion of 
S100A8/9 from ancillary cells in the microenvironment is indeed sufficient to induce genotoxic stress 
in HSCs in a paracrine manner. 
Translating these findings to human disease, exposure of human cord blood CD34+ HSPCs to human 
recombinant S100A8/9 at clinically relevant concentrations (Chen et al., 2013 and Supplemental 
Experimental Procedures) resulted in DNA damage (increased γH2AX foci), apoptosis and impaired 
HSPC function (CFU-C) (Figure S7).  
Activation of the p53-S100A8/9-TLR axis in mesenchymal niche cells predicts leukemic 
evolution and clinical outcome in human low-risk MDS 
To further define the biologic and clinical significance of these findings, we performed transcriptome 
sequencing of CD271+ niche cells in a prospective, homogeneously treated cohort of low-risk MDS 
patients (n = 45, Figure 7A; Table S6).  Expression of S100A8 and S100A9 was strongly correlated 
(Figure 7B, 7C), with a subgroup of MDS patients (17/45; 38%) demonstrating significant 
overexpression of S100A8 and S100A9 (Modified Thompson Tau outlier test) (Figure 7B and 7D), 
independent of established prognostic factors as defined by the revised International Prognostic 
Scoring System (IPSS-R) and the MD Anderson risk score (LR-PSS) (Table S6). Transcriptional 
pathway analysis (GSEA) comparing mesenchymal cells overexpressing S100A8/9 (n = 17) to those 
of niche S100A8/9- patients (n = 28) revealed activation of p53 and TLR programs in S100A8/9+ 
mesenchymal cells (Figure 7E), in line with experimental data from the mouse model pointing at the 
existence of a p53-S100A8/9-TLR axis. Leukemic evolution, defined as the development of frank 
AML or excess of blasts to WHO RAEB1/ RAEB2 (refractory anemia with excess of blasts), occurred 
in 5/17 (29.4%) of niche S100A8/9+ patients (3 AML, 2 RAEB1/RAEB2) vs. 4/28 (14.2%) in niche 
S100A8/9- patients (2AML, 2 RAEB1/RAEB2). Time to leukemic evolution was significantly shorter 
in niche S100A8/9+ patients (average 3.4 (1-7.5) vs 18.5 (7-40); P = 0.03 by Exact Wilcoxon rank 
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sum test) resulting in a significantly shorter progression-free survival of niche S100A8/9+ patients 
(median 11.5 vs 53 months, P = 0.03) (Figure 7F and 7G). Collectively, the data establish activation 
of p53-S100A8/9 signaling in mesenchymal niche cells as an independent predictor of disease 
outcome in human MDS.  
 
DISCUSSION 
Genomic stress and the ensuing DNA damage play a pivotal role in the attenuation of normal 
hematopoiesis in ageing and disease. Mutations accumulate in HSPCs over the lifespan of an 
organism, but the (patho)physiological sources of genomic stress in HSPCs and their relationship 
with human bone marrow failure remain incompletely understood. Here, we show that specific 
inflammatory signals from the mesenchymal niche can induce genotoxic stress in heterotypic 
stem/progenitor cells and relate this concept to the pathogenesis of two human bone marrow failure 
and leukemia predisposition syndromes, SDS and MDS.  
The data indicate that the mesenchymal niche may actively contribute to the formation of a 
‘mutagenic’ environment, adding to our understanding of how a premalignant environment facilitates 
cancer initiation and evolution. The data argue that this may not only occur through facilitated 
selection and expansion of genetic clones that stochastically emerge in a permissive environment, but 
that the mesenchymal niche may be an active participant in driving the genotoxic stress underlying 
tissue failure and malignant transformation of parenchymal cells.  
Notably, leukemic transformation was not observed in mice with targeted deficiency of Sbds in 
mesenchymal cells. Earlier, in a related mouse model of targeted Dicer1 deletion in MPCs, leukemic 
transformation was a rare event (Raaijmakers et al., 2010). In the light of our current findings, these 
observations are likely explained by several factors. First, prolonged exposure to a mutagenic niche, 
beyond the limited lifespan of OCS mice, may be necessary for the accumulation of genetic damage 
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required for full transformation. Additionally, the data argue that DNA repair-proficient HSPCs are 
able to cope with the mutagenic stress induced by their environment through activation of the DDR 
(as shown by molecular activation of cell cycle checkpoints and apoptosis), preventing the 
accumulation of stable genetic damage (as demonstrated by comet assays) and maintaining the 
functional integrity of HSPCs (as shown by repopulation assays). 
We propose that in SDS (and possibly other congenital bone marrow failure syndromes) genetically 
aberrant hematopoietic and niche elements cooperate in driving bone marrow failure and leukemic 
evolution. Our mouse models of SDS support a view in which hematopoietic cell autonomous loss-
of-function of Sbds drives neutropenia (Zambetti et al., 2015), while niche alterations in this disease 
drive myelodysplastic alteration and genotoxic stress. It is conceivable that loss-of-function mutations 
in Sbds in HSPCs further sensitizes HSPCs to the genotoxic effects of the Sbds-deficient environment, 
perhaps through attenuation of DNA damage repair mechanisms. It will thus be of considerable 
interest to test the hypothesis that a mutagenic environment cooperates with aberrant HSPCs, 
compromised in their ability to cope with inflammatory genotoxic stress, in leukemia evolution. In 
this context, the propensity of Sbds-deficient cells to accumulate ROS (Ambekar et al., 2010), and 
their reduced ability to cope with various cellular stressors such as mitotic spindle destabilizing 
agents, endoplasmic reticulum stress activators, topoisomerase inhibitors and UV irradiation (Austin 
et al., 2008; Ball et al., 2009) is noteworthy.  
The current findings add to emerging insights into the role of innate immune TLR-signaling in the 
pathogenesis of human MDS. TLR4 and other TLRs are overexpressed in HSPCs from MDS patients 
(Maratheftis et al., 2007; Wei et al., 2013) and TLR4 expression was shown to correlate with 
apoptosis in CD34+ hematopoietic cells. TLR signaling is constitutively activated in MDS mice with 
deletion of chromosome 5 (del5q) (Starczynowski et al., 2010) and multiple TLR downstream 
signaling pathways have been shown to be activated in MDS and related to loss of progenitor cell 
function (Ganan-Gomez et al., 2015).  
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Our findings implicate the DAMP S100A8/9 derived from the mesenchymal niche as a driver of TLR 
signaling in this disease. The unbiased identification of S100A8/9 seems to independently converge 
with an earlier report implicating S100A8/9 in the pathogenesis of MDS (Chen et al., 2013). In this 
study it was shown that the plasma concentration of S100A9 was significantly increased in MDS 
patients (Chen et al., 2013) and S100A8/9 was shown to drive expansion and activation of myeloid-
derived suppressor cells (MDSCs) that contributed to cytopenia and myelodysplasia in a murine 
model of S100A9 overexpression through secretion of suppressive cytokines. It is therefore an 
intriguing possibility that additional, indirect, biologic effects of S100A8/9 contribute to the 
hematopoietic phenotype of OCS mice. This may include engagement of other cognate receptors of 
the protein, including expansion of MDSCs through CD33 signaling (Chen et al., 2013).  
In our study S100A8/9 was aberrantly overexpressed in a rare population of mesenchymal niche cells, 
both in the mouse model and human disease. Typically, expression of the protein is found in myeloid 
cells, raising the question why S100A8/9 production by (rare) niche cells is more relevant to the 
biology of HSPC than secretion from myeloid/erythroid cells. While the answer to this question 
remains speculative in the absence of in vivo targeted overexpression studies, it is noteworthy that, in 
contrast to most cytokines, chemokines and other pro-inflammatory molecules, the local 
accumulation of S100A8/9 in the environment is very high (up to 100μg/ml and about 50 to 100-fold 
higher than systemic concentrations), likely caused by attachment to extracellular matrices such as 
proteoglycans (Vogl et al., 2014). This implicates that the exposure of HSPCs to S100A8/9 is 
projected to relate strongly to their anatomical proximity to a producing cell. CD271+ mesenchymal 
cells are directly adjacent to CD34+ HSPC in human bone marrow (Flores-Figueroa et al., 2012). This 
notion of ‘spatial relevance’ may also be congruent with recent observations that aberrant 
overexpression of S100A8/9 in hematopoietic (erythroid) cells within the erythroid island in a model 
of human 5q- syndrome leads to a predominant erythroid, anemic, phenotype (Schneider at al., 2016). 
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The mechanisms of S100A8/9 induced DNA damage remain to be fully elucidated. Our experiments 
using NAC to reduce ROS burden suggest an incomplete association between oxidative stress and 
DNA damage, suggesting that S100A8/9 secretion may attenuate genomic integrity through 
additional mechanisms. Similarly, it is conceivable that other ligands secreted from mesenchymal 
cells contribute to the induction of DNA damage in HSPCs in the mouse model. We found a striking 
abundance of transcripts encoding other DAMPs and cytotoxic proteins in both the mouse model and 
mesenchymal elements isolated from SDS patients. Ongoing investigations will have to assess 
whether other selected ligands can evoke genomic stress in heterotypic HSPCs and in such a fashion 
contribute to the generation of a mutagenic environment in these disorders. 
 Finally, our findings establish molecular characteristics of the mesenchymal environment as an 
important determinant of disease outcome in humans. S100A8/9 expression, associated with activated 
p53 and TLR signaling, in mesenchymal cells predicted leukemic evolution and progression-free 
survival in a cohort of homogeneously treated low-risk MDS patients. This is of considerable clinical 
relevance because low-risk MDS is a heterogeneous disease-entity with a subset of patients having a 
particular dismal prognosis not identified by current risk-stratification strategies (Bejar et al., 2012). 
Gene expression of S100A8/9 may identify a substantial subset of patients with a survival typically 
associated with ‘high-risk’ patients and, if confirmed in larger independent cohorts, could guide 
therapeutic decision making in MDS. The data thus provide a strong rationale for niche–instructed 
therapeutic targeting of inflammatory signaling in human preleukemic disease. 
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EXPERIMENTAL PROCEDURES 
Mice and in vivo procedures 
OCS, Trp53f/f and S100A9Tg mice have been previously described (Cheng et al., 2008; Jonkers et al., 
2001; Raaijmakers et al., 2010). PtprcaPepcb/BoyCrl (B6.SJL) mice were purchased from Charles 
River. Animals were maintained in specific pathogen free conditions in the Experimental Animal 
Center of Erasmus MC (EDC). For in vivo cell cycle analysis, OCS mice received intraperitoneal 
injections of BrdU (1.5 mg in PBS, BD Biosciences) and sacrificed after 15 h. For TLR4 studies, 2 
week-old mice were intraperitoneally injected with a double dose (100 µg and 35 µg, 48 h interval) 
of TLR4-neutralizing antibody (clone MTS510, eBioscience) or isotype control (clone eBR2a, 
eBioscience) and sacrificed after 60h. For NAC rescue studies, 2-week-old mice received daily 
intraperitoneal injections of NAC (Sigma-Aldrich, 320 mg/kg in saline) until the day of the analysis 
and at least for 5 days. All mice were sacrificed by cervical dislocation. Animal studies were approved 
by the Animal Welfare/Ethics Committee of the EDC in accordance with legislation in the 
Netherlands (Approval No. EMC 2067, 2714, 2892, 3062). 
μCT analysis 
Femur bones were isolated, fixated in 3% PFA/PBS for 24 h and stored in 70% ethanol. μCT analysis 
was performed using a SkyScan 1172 system (SkyScan) using previously described settings (Tudpor 
et al., 2015). Bone microarchitectural parameters relative to the trabecular and the cortical area were 
determined in the distal metaphysis and the mid-diaphysis of each femur, respectively, using software 
packages from Bruker MicroCT (NRecon, CtAn and Dataviewer).  
Human bone marrow samples 
Bone marrow aspirates were obtained from SDS and DBA patients during routine follow-up. All 
MDS patients were treated with lenalidomide (10 mg/day, d 1-21 in a 4-week schedule) in the context 
of an ongoing prospective clinical trial for patients with low or intermediate-1 risk MDS according 
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to IPSS criteria (HOVON89; www.hovon.nl; www.trialregister.nl as NTR1825; EudraCT No. 2008-
002195-10). Bone marrow specimens were collected at study entry and disease diagnosis and staging 
confirmed by central board reviewing. Leukemic evolution was assessed according to WHO criteria; 
development of RAEB1 (refractory anemia with excess of blast) or RAEB-2 (if RAEB1 at entry) was 
considered progression of disease. Leukemia (AML) was diagnosed according to standard WHO 
criteria (≥20% myeloblasts in blood/bone marrow). Bone marrow cells from allogeneic 
transplantation donors were used as normal controls. Patients and healthy donor characteristics are 
described in Table S4 and S6. All specimens were collected with informed consent, in accordance 
with the Declaration of Helsinki 
Gene expression profiling 
Osx::GFP cells from bone cell suspensions of OCS mice were sorted in TRIzol Reagent (Life 
Technologies) and RNA was extracted according to the manufacturer’s recommendations. Linear 
amplification of mRNA was performed using the Ovation Pico WTA System (NuGEN). cDNA was 
fragmented and labelled with  Encore™ Biotin Module (NuGEN). The biotinylated cDNA was 
hybridized to the GeneChip Mouse Genome 430 2.0 Array (Affymetrix eBioscience). Signal was 
normalized and differential gene expression analysis was performed with the limma package (Ritchie 
et al., 2015). RNA sequencing experiments were performed as previously described (Zambetti et al., 
2015). Human transcripts were aligned to the Ref Seq transcriptome (hg19) and analyzed with 
DESeq2 (Love et al., 2014), while mouse transcripts were aligned to the Ensembl transcriptome 
(mm10) and analyzed with EdgeR (Robinson et al., 2010) in the R environment. FPKM values were 
calculated using Cufflinks (Trapnell et al., 2010). Principal component analysis was performed in the 
R environment on the raw fragment counts extracted from the BAM files by HTSeq-count (Anders 
et al., 2015). For Gene Set Enrichment Analysis (Subramanian et al., 2005) (GSEA, Broad Institute), 
normalized intensity values (microarray data) and FPKM values (RNA sequencing) were compared 
to the curated gene sets (C2) and the Gene Ontology gene sets (C5) of the Molecular Signature 
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Database (MsigDB) using the Signal2Noise metric and 1000 gene set-based permutations. For 
HSPCs GO-term analysis, genes with significantly differential expression (P<0.05) were interrogated 
using g:Profiler web-based software (Reimand et al., 2011; Reimand et al., 2007). 
Immunofluorescence microscopy 
HSPCs were harvested in PBS+0.5%FBS, cytospun on a glass slide for 3 min at 500 rpm using a 
Cytospin 4 centrifuge (Thermo Scientific) and fixed in 3% PFA/PBS for 15 min on ice. After 3 
washing steps in PBS, cells were permeabilized for 2 min in 0.15% Triton-X100/PBS. Aspecific 
binding sites were blocked by incubation in 1%BSA/PBS for 1 h at room temperature. Cells were 
next stained overnight at 4°C with either anti-phospho-histone H2A.X (Ser139) mouse monoclonal 
antibody (clone JBW301, Merck Millipore, diluted 1:1000 in 1%BSA/PBS) or with anti-53BP1 rabbit 
polyclonal antibody (Novus Biologicals, diluted 1:1000 in 1%BSA/PBS). Slides were washed twice 
in PBS for 5 min and incubated for 1 h at 37°C with either Alexa Fluor 488-conjugated goat anti-
mouse antibody (Cat. A10667, Life Technologies) or goat anti-rabbit antibody (Cat. A11008, Life 
Technologies), both diluted 1:200 in 1%BSA/PBS. After 2 washes in PBS, slides were mounted in 
VECTASHIELD Mounting Medium with DAPI (Vector Laboratories). Z-series images were 
acquired with a Leica TCS SP5 confocal microscope (63X objective lens) using the LAS software 
(Leica Microsystems). γH2AX and 53BP1 foci were counted manually from the maximum projection 
view. 
Survival analysis 
The low-risk MDS patient subgroup with S100 niche signature was defined by the Modified 
Thompson Tau test for outlier detection. In brief, S100A8 statistics from the control cases were 
combined to define the rejection region, demarcating FPKM values to be considered as outliers. MDS 
cases with S100A8 FPKM values within the rejection region were thus defined as niche-signature+. 
To determine the significance difference in time to progression we used the Wilcoxon signed rank 
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test accounting for tied observations. Event-free survival was determined by specifying leukemic 
progression or death as events. Patients experiencing a non-hematological related death (e.g., cardiac 
failure), where censored on the date of this event. Patients remaining alive were censored on the date 
of last consultation. Kaplan-Meier curves were used to estimate the survival functions through time. 
Statistical differences in the survival distributions was assessed with the Mantel-Cox log-rank test. 
All calculations were performed in the R environment.  
Statistics 
Statistical analysis was performed using Prism 5 (GraphPad Software). Unless otherwise specified, 
unpaired, 2-tailed Student’s t test (single test) or 1-way analysis of variance (multiple comparisons) 
were used to evaluate statistical significance, defined as P<0.05. All results in bar graphs are mean 
value ± standard error of the mean. 
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FIGURE LEGENDS 
Figure 1. Deletion of Sbds in MPCs recapitulates skeletal defects in human SDS. (A-B) Impaired 
growth in OCSf/f mice: (A) body weight (n = 9) and (B) femur length (n = 5). (C-H) Femur μCT 
analysis of OCSf/+ (n = 5) and OCSf/f (n = 4) mice. (C) Representative 2D-images. Left: longitudinal 
view. Right: cortical bone. (D) 3D-image. (E) Bone volume per tissue volume (BV/TV). (F) 
Trabecular number (Tb. N). (G) Trabecular spacing (Tb. Sp). (H) Cortical bone mineral density 
(BMD). (I) Goldner osteoblast staining (OCSf/+, n = 6; OCSf/f, n = 8). Left: representative images 
(arrows: osteoblasts; with white dashed line in the magnified region). Right: number of osteoblasts 
per bone perimeter (N.Ob/B.Pm). (J-K) 3-point bending test indicating (J) reduced resistant to 
fracture and (K) decreased stiffness of OCSf/f bone (OCSf/+, n = 5; OCSf/f, n = 4). *P<0.05. **P< 
0.01. ***P<0.001. Data are mean ± SEM. See also Figure S1. 
Figure 2. Sbds-deficient mesenchymal cells induce genotoxic stress in HSPCs. (A) Transcriptional 
network analysis indicating mitochondrial dysregulation in mutant HSPCs. NES: Normalized 
Enrichment Score. (B-C) Increased mitochondrial potential (TMRM) in HSPCs: (B) representative 
plots; (C) mean fluorescence intensity (MFI) (n = 3). (D) ROS quantification by CM-H2DCFDA 
(OCSf/+, n = 6; OCSf/f, n = 7). (E) Increased γH2AX levels in mutant HSPCs. Left, representative 
FACS analysis. Right, MFI values (n = 4). (F-I) Activation of DNA damage response in mutant 
HSPCs. (F) Transcriptional repression of G1-S checkpoint progression. (G, H) In vivo BrdU staining 
confirming impaired S-phase transition (n = 4). (I) Downregulation of Myc signaling. GSEA data 
shown is from CD48- LKS cells. a.u., arbitrary units.  †††FDR<0.001. *P<0.05. **P<0.01. 
***P<0.001. Data in bar graphs are mean± SEM. See also Figure S2, S3, S6 and Table S1-S3. 
Figure 3. Activation of p53 in MPCs drives skeletal and hematopoietic abnormalities in OCS 
mutants. (A) p53 protein (FACS) accumulates in GFP+ cells from OCSf/f mice (n = 3). (B-C) 
Activation of p53 in mutant GFP+ cells as demonstrated by (B) enrichment of a p53 GSEA signature 
and (C) overexpression of canonical p53 targets (n = 3). (D) Schematic representation of the p53 
29 
 
floxed allele with indication of primers used to assess genotypes (p10.1-p10.2) and genomic deletion 
(p1.1-p10.2). (E) Specific deletion of p53 in bone-containing tissue in OCSf/f p53Δ mice (genomic 
PCR). (F-J) µCT analysis indicating normalization of bone mass in OCSf/f mice upon genetic deletion 
of p53 (p53+, n = 3; p53Δ, n = 5). Tb. Pf , Trabecular bone pattern factor. (K) Bone mineral density 
in OCSf/f mice is not rescued by p53 deletion. (L-M) Effects of p53 deficiency on OCS HSPCs. 
Tendency for reduced oxidative stress as assessed by DHE analysis (L) and significant reduction of 
γH2AX levels (M) in HSPCs from OCSf/f p53Δ mice (n = 3). MFI: mean fluorescence intensity. a.u., 
arbitrary units.  *P < 0.05. **P <0.01. ***P <0.001. Data are mean ± SEM. See also Figure S4. 
Figure 4. Identification of S100A8 and S100A9 as candidate drivers of genotoxic stress in 
leukemia predisposition syndromes. (A) Representative mesenchymal CD271+ FACS gating. (B) 
Pathognomonic 183-184 TA>CT mutation in niche cells from a representative SDS patient (IGV 
plot). (C) Reduced SBDS expression in SDS niche cells. (D) Disruption of ribosome biogenesis and 
translation in SDS CD271+ cells (GSEA). (E) Inflammation-related transcripts are upregulated in 
niche cells from SDS patients and OCSf/f mice. (F) Significantly differentially expressed genes in 
SDS (n = 4), MDS (n = 9) and DBA (n = 3) in comparison to normal CD271+ cells. (G) Expression 
of S100A8 and S100A9 in mesenchymal cells from SDS, low-risk MDS, and DBA patients. *P<0.05. 
***P<0.001. †††FDR-adjusted P<0.001. See also Figure S1, S5 and Table S4. 
Figure 5. S100A8/9 induces genotoxic stress in murine HSPCs through TLR4 signaling. (A-B) 
Increased S100A8 and S100A9 levels in OCSf/f GFP+ cells. (A) representative plots. (B) MFI values 
(n = 5). (C) Increased plasma concentration of S100A8/9 by ELISA (OCSf/+, n = 5; OCSf/f, n = 4). 
(D) Left: representative γH2AX pictures after HSPCs in vitro exposure. Positive control: 8-Gy 
irradiated Lin- c-Kit+ Sca-1- cells. Negative controls: heat-inactivated S100A8/9 (H.I. ctr). Right: 
number of γH2AX foci (n = 3). (E) S100A8/9 has no effect on cell cycle (n = 2). (F) Increased 
apoptosis in S100A8/9-exposed LKS (n = 3). (G) Activation of TLR signaling (GSEA). (H) TLR4-
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blocking antibodies limit DNA damage in OCSf/f mice (n = 4). *P<0.05. *P<0.01. ***P<0.001. Data 
are mean ± SEM. See also Figure S6 and S7; Table S5. 
Figure 6. Niche derived S100A8/9 induces oxidative and genotoxic stress in HSPCs. (A) 
Schematic representation of wild type HSPCs transplantation in S100A9Tg mice. BM: bone marrow. 
(B-C) Mesenchymal cells from S100A9Tg mice express the S100A9-IRES-GFP construct. (B) 
Gating strategy defining CD51+ Sca-1+ mesenchymal ‘stem’ cells (MSC) and CD51+ Sca-1- 
osteolineage cells in the microenvironment (C) Expression of GFP in S100A9Tg-derived 
mesenchymal compartments (n = 3). (D) Transplantation efficiency as assessed by CD45.1+ cell 
chimerism in the bone marrow (BM) of transplanted mice (n = 4). (E) Accumulation of superoxide 
radicals in HSPCs exposed to S100A8/9-overexpressing microenvironment. Left, representative plot. 
Right, DHE MFI values (n = 4). (F) Increased levels of γH2AX in immunophenotypically-defined 
HSCs. Left, representative plot. Right, DHE MFI values (n = 4). *P<0.05. **P<0.01. Data are mean 
± SEM. 
Figure 7. Activation of the p53-S100A8/9-TLR axis in mesenchymal niche cells predicts 
leukemic evolution and clinical outcome in human low-risk MDS. (A) Representative examples 
of FACS-isolated CD271+ niche cells in human MDS. (B) Correlation plot of S100A8 and S100A9 
expression levels in human low-risk MDS (n = 45). (C) Expression of the defining gene NGFR 
(CD271) in mesenchymal  cells (S100 niche +, n = 17; S100 niche -, n = 28). (D) Representative 
staining of S100A8 and S100A9 in endosteal (CD271+) stromal cells. Intramedullary staining reflects 
expression of S100A8/9 in myeloid cells. (E) GSEA analysis indicating enrichment of p53 and TLR 
signatures in S100A8/9-overexpressing CD271+ cells. Two representative GSEA plots are shown. 
NES: Normalized Enrichment Score.  (F) Kaplan-Meier survival curve showing progression-free 
survival (G). Statistical analysis indicating significantly reduced time to progression and progression-
free survival (PFS). See also Table S6. 
 
Figure 1 Click here to download Figure Figure 1.tif 
Figure 2 Click here to download Figure Figure 2.tif 
Figure 3 Click here to download Figure Figure 3.tif 
Figure 4 Click here to download Figure Figure 4.tif 
Figure 5 Click here to download Figure Figure 5.tif 
Figure 6 Click here to download Figure Figure 6.tif 
Figure 7 Click here to download Figure Figure 7.tif 
1 
 
SUPPLEMENTAL DATA ITEMS 
 
 
 
Figure S1. Related to Figure 1; Figure 4. Impairment of terminal osteogenic differentiation in OCSf/f mice. (A) 
Increased CFU-F numbers (n = 3) with (B) unaltered frequency of Osx::GFP+ cells (n = 4) in OCSf/f mice. (C) Depletion 
of transcripts defining terminal osteogenic differentiation (osteocalcin, Bglap) and dentin matrix acidic phosphoprotein 1 
(Dmp1), critical for proper mineralization of bone, and enrichment of markers of bone progenitor cells or early osteoblasts 
(Runx2 and Col1a1) in GFP+ cells from OCSf/f mice. No statistically significant difference was observed in the expression 
of osterix (Sp7).  (D) Significant (FDR<0.25) enrichment of ribosome and peptide chain elongation signatures in OCSf/f 
GFP+ cells (GSEA) with (E) representative plots. *P<0.05. **P<0.01. Data are mean ± SEM. 
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Figure S2. Related to Figure 2. Oxidative and genotoxic stress in HSPCs from OCSf/f mice. (A-C) unaltered HSPC 
numbers in OCSf/f mice: (A) representative FACS plots, (B) bone marrow cellularity and (C) subset frequency (OCSf/+, 
n = 8 in A-B, n = 7 in C; OCSf/f, n = 7). LK: Lin- c-Kit+ Sca-1- cells. LKS: Lin- c-Kit+ Sca-1+ cells. MPP: multipotent 
progenitors, CD48- CD150- LKS cells. SLAM: CD48- CD150+ LKS cells. (D) FACS isolation of CD48+ and CD48- HSPC 
subsets for RNA-seq (OCSf/+ CD48-, n = 3; other groups, n = 4). (E) RNA-seq validation confirming CD48 and Ptprc 
(CD45) expression and the Sbds-proficient status of HSPCs from mutant mice. (F) Principal component analysis 
indicating global preservation of the transcriptome in HSPCs from OCSf/f mice. (G) Superoxide radical accumulation in 
HSPCs from OCSf/f mice as shown by DHE staining. (H) Increased number of γH2AX foci in HSPCs from mutants (n = 
2; pooled data). (I-J) NAC treatment attenuates oxidative (I) and (non-significantly) genotoxic stress (J) of OCSf/f mice. 
NAC- controls were either treated with saline or not injected. (OCSf/+ + NAC, n = 3; OCSf/f + NAC, n = 3;, n = 4; other 
groups, n = 5). (K) Ki67 analysis of OCS mice indicating no change in the frequency of G0 HSPCs (OCSf/+, n = 3; OCSf/f, 
n = 4). *P<0.05. **P<0.01. ***P<0.001. †††FDR-adjusted P<0.001. Data are mean ± SEM. 
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Figure S3. Related to Figure 2. Niche-induced DNA damage does not affect HSPC function. (A) Schematic 
representation of the competitive transplantation. BM: bone marrow. (B) Peripheral blood frequency of CD45.2+ cells 16 
weeks after transplantation. (C) Bone marrow frequency of CD45.2+ cells (21-32 weeks after transplantation). Every 
circle represents one recipient mouse. (D) Manual scoring system applied to comet assay analysis. (E) Comet assay 
showing similar frequency of highly damaged HSPCs in OCSf/+ and OCSf/f mice (n = 5). +IR: 8-10 Gy irradiated positive 
control (LK cells). ***P<0.001. Data are mean ± SEM. 
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Figure S4. Related to Figure 3. Bone effects of Trp53 ablation in OCS mutant and control mice. (A-D) Normalization 
of µCT parameters  in OCSf/f p53Δ mice shown as fold change (p53+, n = 3; p53Δ, n = 5). (E-F) Modest increase in bone 
mass upon genetic deletion of p53 in OCS control mice, defined as Osxcre/+ Sbdsf/+ or Osxcre/+ Sbds+/+ (p53f/+, n = 8; p53f/f, 
n = 3). *P<0.05. **P<0.01. ***P<0.001.  Data are mean ± SEM. 
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Figure S5. Related to Figure 4. SBDS mutations in mesenchymal cells from SDS patients. (A-B) Detection of 258+2 
T>C mutation in SDS patients. (A) Representative IGV plot. Note that the coverage level after the cryptic site (dashed 
box) is reduced in SDS, indicating an 8-bp deletion. (B) Quantification of 258+2 T>C mutation as frequency of spliced 
reads with 8-bp deletion. Every circle represents a patient. (C) Nucleotide sequence in positions 183-184 from SDS 
patients and healthy donors. 
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Figure S6. Related to Figure 2; Figure 5. A p53-S100A8/9-TLR axis induces DNA damage in HSPCs. (A) Sbds-
knock down in OP9 cells induces expression of S100a8, S100a9 and activation of p53 pathway. Left, expression analysis 
by qPCR (data normalized against shControl, n = 3). Right, representative Western Blot analysis showing p53 
accumulation upon Sbds-knock down. (B, C) TLR4 expression and activation of NF-κB and MAPK pathways in HSPCs 
from OCSf/f mice (GSEA). NES: normalized enrichment score. (D) Ex-vivo treatment with S100A8/9 induces 53BP1 foci 
of DNA damage in murine HSPCs (LKS cells), Left, representative images. Right, cumulative dot plots (n = 2). ***P 
<0.001. Data in bar graphs are mean ± SEM. 
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Figure S7. Related to Figure 5. S100A8/9 drives genomic stress in human HSPCs. (A-C) Treatment of human CD34+ 
HSPCs with recombinant S100A8/9. (A) Induction of γH2AX foci (n = 3). (B-C) Increased frequency of apoptotic cells. 
(B) Representative plot. (C) Quantification (n = 3).  (D) Reduced colony forming capacity of HSPCs as assessed by CFU-
C assay (n = 4 independent experiments in triplicate). Data are mean ± SEM. *P<0.05. **P<0.01. ***P<0.001. 
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Table S1. Related to Figure 2. Transcriptional profiling of OCS-derived HSPCs reveals dysregulation of signatures 
previously identified as predictive for leukemia evolution. Provided as an Excel file. Upregulation of G-protein-
coupled receptors and cell adhesion-communication, and downregulation of mitochondrial oxidative phosphorylation, 
ribosome biogenesis, aminoacyl-tRNA synthetase activity, proteasomal degradation, citric acid cycle, cell cycle 
deregulation and hematopoietic stem cell programs. Normalized enrichment score (NES) and False Discovery Rate-
adjusted q-value (FDR) are omitted when FDR > 0.25. 
 
 
Table S2. Related to Figure 2. Stress and DNA damage dysregulation in the transcriptome of HSPCs from OCSf/f 
mice.  
 
Genes with significantly different expression (P<0.05) between OCSf/+ and OCSf/f mice within the CD48- or CD48+ 
populations were interrogated for GO and Reactome term enrichment using g-profiler. P-val: p-value. NS: not significant 
(P≥0.05). 
  
10 
 
Table S3. Related to Figure 2. Myc-related signatures depleted in OCSf/f HSPCs. 
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Table S4. Related to Figure 4. Human normal donor and patient characteristics.  
  
aAll SDS patients were genetically characterized by compound heterozygosity c.183_184TA>CT/c.258+2T>C. Patients 
did not receive G-CSF treatment and were not diagnosed with MDS or AML at the time of bone marrow sampling. All 
patients presented with pancreatic insufficiency (serum trypsinogen level <6 µg/L) and growth retardation (≤ 2 SD). All 
patients but SDS438 were neutropenic at sampling (absolute neutrophil counts, ANC < 1.5×109/l); SDS438 had ANC = 
1.62×109/l). 
bSee Table S6 for further patient characteristics. 
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Table S5. Related to Figure S5. In vitro exposure of HSPCs to S100A8/9 activates transcriptional signatures related 
to TLR signaling and cellular stress/apoptosis.  
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Table S6. Related to Figure 7. MDS patient characteristics. Provided as an Excel file. All patients were treated with 
lenalidomide in the context of an ongoing prospective clinical trial (details in Experimental Procedures). Patient 
characteristics at study entry are listed.  Progression free survival is calculated from date of study-entry.  Hb, hemoglobin. 
PLT, platelets. WBC, white blood cells. ANC, absolute neutrophil count. S100A8 and S100A9 expression is obtained by 
RNA-sequencing data. P-values were calculated by Mann-Whitney (MW) test.  
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
Mice genotyping and sample collection 
DNA was extracted from mouse toes with DirectPCR Lysis Reagent (Viagen Biotech). Genotyping and Cre-mediated 
recombination were verified on genomic DNA samples using the primers listed in the table below. Mouse bone marrow 
and bone fraction cells were isolated as previously described (Raaijmakers et al., 2010). Red blood cells (RBC) were 
lysed with ACK lysing buffer (Lonza) before surface markers staining. Peripheral blood was collected from the 
submandibular vein in K2EDTA-coated microtainers (BD) and analyzed using a Vet ABC counter (Scil Animal Care). 
 
Genotyping primers used in the study. 
 
 
Bone mineral density and 3-point bending test analysis 
Cortical BMD was calculated from μCT cortical data on the basis of a calibration scanning obtained using two phantoms 
with known density (0.25 g/cm3 and 0.75 g/cm3; Bruker MicroCT) under identical conditions as for the femurs. For the 
bending test, femurs were placed in a custom-modified Single Column Lloyd LRX System bending device (Lloyd 
Instruments) and analyzed as previously reported (van der Eerden et al., 2013) using CtAnalyzer software (Bruker 
MicroCT). 
Goldner’s Masson trichrome staining 
Femurs were embedded in methylmetacrylate as indicated before (Derkx et al., 1998). Sections of 6 μm were deacrylated, 
hydrated and stained accordingly to the previously described protocol (Gruber, 1992). Images of the metaphysial area 
were captured with a Nikon Eclipse E400 system (Nikon) using a 20X objective lens. Data was analyzed using Image J 
software (http://imagej.nih.gov/ij/). Briefly, the bone surface was manually selected and the perimeter length calculated. 
Osteoblasts were manually identified based on staining and morphology. The frequency of osteoblasts was calculated as 
percentage of osteoblast area in the bone surface and as number of osteoblasts per mm of bone.  
CFU-F assay 
Primary bone fraction cells were resuspended in growth medium, consistent of αMEM, 20% FBS (Life Technologies), 
and Penicillin-Streptomycin solution (Life Technologies), and cultured under hypoxic conditions (5% O2, 5% CO2) in 
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24-well plates (seeding density: 6.5 x 104 cells/cm2). After 24h, the medium was changed to eliminate non-adherent cells. 
Colonies were stained after 7 days of culture. Briefly, medium was removed and cells were fixed 5’ in methanol, stained 
in a 1:20 dilution of Giemsa staining (Merck Millipore) in distilled water and rinsed with tap water. Colonies were counted 
with an Olympus CK2 inverted microscope, using a 10X magnification.  
Primary cell isolation and flow cytometry 
All FACS antibodies incubations were performed in PBS+0.5%FCS for 20 min on ice. To identify hematopoietic stem 
and progenitor cells (HSPCs), bone marrow cells were first co-stained with a cocktail of biotin-labelled antibodies against 
the following lineage (Lin) markers: Gr1 (RB6-8C5), Mac1 (M1/70), Ter119 (TER-119), CD3e (145-2C11), CD4 
(GK1.5), CD8 (53-6.7) and B220 (RA3-6B2) (all from BD Biosciences). After washing, cells were incubated with Pacific 
Orange-conjugated streptavidin (Life Technologies) and the following antibodies: Pacific Blue anti-Sca1 (D7), FITC or 
PE anti-CD48 (HM48-1), PE-Cy7 anti-CD150 (TC15-12F12.2) (all from Biolegend), APC anti-c-Kit (2B8, BD 
Biosciences).  
To analyze differentiated cells and define chimerism, we used FITC anti-Gr1 (RB6-8C5), APC anti-Mac1 (M1/70), PE 
anti-B220 (RA3-6B2), APC-Cy7 anti-CD45.1 (A20), PE-Cy7 anti-CD45.2 (104), all from Biolegend. To identify stromal 
cells, bone fraction cell suspension was stained with the following antibodies: APC-Cy7 anti-CD45.2 (104), BV510 anti-
Ter119 (TER-119), PE-Cy7 anti-CD105 (MJ7/18), PE anti-CD51 (RMV-7), Pacific Blue anti-Sca1 (D7) (all from 
Biolegend), PE-CF594 anti-CD31 (MEC 13.3, BD Biosciences).  
For human mesenchymal cell isolation, bone marrow aspirates were diluted 1:25 with red blood cell lysis solution (NH4Cl 
0.155 M, KHCO3 0.01 M, EDTA-Na2.2H2O 0.1 M, pH 7.4) and incubated for 10 min at room temperature. Cells were 
collected by centrifugation and washed once with PBS+0.5%FBS. For FACS sorting, immunostaining was performed 
with the same protocol used for murine bone marrow, using PE CD271 (ME20.4) and PE-Cy7 CD45 (HI30) antibodies 
(Biolegend). CD271+ cells did not contain erythroid cells based on staining with BV421 CD235a (GA-R2, BD 
Biosciences). 
Apoptosis was assayed with FITC Annexin V Apoptosis Detection Kit I (BD Biosciences) according to the 
recommendation of the manufacturer. Dead cells were excluded based on 7AAD staining.  
The content of p53 in stromal cells was analyzed after cell surface antibody staining and cell permeabilization, obtained 
with Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences), by incubating cells with Alexa Fluor 
647 anti-p53 (1C12) diluted in 1X Perm/Wash buffer (BD Biosciences).  
γH2AX levels were assessed in cells fixed and permeabilized with Cytofix/Cytoperm Fixation/Permeabilization Solution 
Kit (BD Biosciences) by incubating cells with Alexa Fluor 647 anti-γH2AX (N1-431, BD Biosciences) diluted in 1X 
Perm/Wash buffer (BD Biosciences). 
All FACS events were recorded using a BD LSR II Flow Cytometer and analyzed with FlowJo 7.6.5 software (Tree Star). 
Cells were sorted with a BD FACSAria III. 
SBDS mutation analysis 
Mutations in SBDS were evaluated in the RNA sequencing data of SDS patients and healthy controls using the Integrative 
Genomics Viewer (IGV) (Robinson et al., 2011). The c.183_184TA>CT mutation was quantified by annotating the 
number of reads presenting each of the four different nucleotides for both the positions 183 and 184. Because of its 
intronic position, the c.258+2T>C mutation was assessed by quantifying the usage of the 251-252 cryptic donor site 
(Boocock et al., 2003). Specifically, we quantified the fraction of spliced reads with an 8-bp deletion (nucleotides 251-
258) as an indication of the mutated genotype. 
Mitochondrial membrane potential quantification 
After staining cells for surface antigens, cells were washed in PBS+0.5%FBS and centrifuged. Cells were resuspended in 
PBS+0.5%FBS  and tetramethylrhodamine methyl ester (TMRM, Life Technologies) was added from a 10 μM stock 
solution in DMSO to a final non-quenching concentration of 100 nM. After incubation for 20 min at 37°C, cells were 
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washed with PBS+0.5%FBS and analyzed. Cells treated with 1 μM p-trifluoromethoxy carbonyl cyanide phenyl 
hydrazone (FCCP) were used as positive control for membrane depolarization. 
ROS detection 
After surface antigen staining, cells washed in PBS+0.5%FBS and centrifuged. A stock solution of 2.5 μg/μl 5-(and-6)-
chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA, Life Technologies) in DMSO was 
diluted with PBS+0.5%FBS to a final concentration of 3 μg/μl. Cells were resuspended with the CM-H2DCFDA solution 
and stained for 20 min at 37°C, washed in PBS+0.5%FBS and analyzed. 
For dihydroethidium (DHE) studies, the compound (Sigma Aldrich) was reconstituted to a 10mM solution in DMSO. 
After surface antigen staining and washing, cells were resuspended in 500 µl of diluted DHE solution (1:10,000 in HBSS) 
and incubated at 37°C for 30 min, then washed in PBS+0.5%FBS and analyzed. 
Cell cycle analysis 
Mice labeled in vivo by BrdU were sacrificed and bone marrow cells were stained for surface antigen. BrdU staining was 
performed using the FITC BrdU Flow Kit (BD Biosciences) following the manufacturer’s instructions. 
For Ki67-based cell cycle analysis, cultured or freshly isolated cells were first stained for surface markers and then fixed 
and permeabilized with Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences). After washing, cells 
were incubated cells with FITC anti-Ki67 (B56, BD Biosciences) diluted in 1X Perm/Wash buffer (BD Biosciences) for 
20 min and then washed. Cells were resuspended in PBS+0.5%FBS and 7AAD was added to detect DNA. 
Alkaline comet assay 
HSPCs were resuspended in 0.7% low melting agarose (Sigma-Aldrich) in PBS at a concentration of 105 cells/ml. 50 μl 
of cell suspension were spread on CometSlides (Trevigen) and the agarose was allowed to solidify for 30 min at 4°C. 
Slides were incubated for 1 h at 4°C in lysis buffer (1% Triton-X100 freshly added to 2.5M NaCl, 100 mM EDTA, 10 
mM Tris/pH10 solution) protected from light and placed in an electrophoresis tray. After 20 min incubation in alkaline 
solution (200mM NaOH, 1mM EDTA, freshly prepared), unwound DNA was run in the same solution for 30 min at 1 
V/cm. After electrophoresis, slides were washed twice in distilled water for 5 min, fixated in 70% ethanol for 5 min and 
allowed to dry at 37°C. DNA was stained for 5 min in SYBR Gold (Life Technologies), washed in distilled water and 
allowed to dry in the dark. Images were captured with a Leica DMRXA fluorescent microscope (10X magnification). 
DNA damage severity was manually quantified according to the score system depicted in Figure S3D.  
Bone marrow transplantation 
For serial (competitive) transplantation studies, bone marrow cells from OCS and BL6.SJL mice were isolated and RBC-
depleted as described above. BL6.SJL cells were mixed in a 1:1 ratio with cells from OCSf/+ of OCSf/f mice. 9 week-old 
B6.SJL mice were lethally irradiated (8.5Gy) and transplanted with a total of 106 bone marrow cells.  
For transplantation in S100A9Tg mice, donor bone marrow cells were isolated from 12-week old BL6.SJL mice and 
transplanted into lethally irradiated (8.5Gy) C57BL/6 or S100A9Tg mice (F10 backcross in C57BL76). Each mouse 
received 2x106 bone marrow cells by tail vein injection and was sacrificed one month after transplantation.  
In all transplantation experiment, recipients received antibiotics in the drinking water for 2 weeks after transplantation. 
S100A8/9 measurements 
To quantify intracellular levels of S100A8/9 proteins, bone fraction cell suspensions were first stained for surface markers 
and next fixated and permeabilized with Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (BD Biosciences) 
according to the manufacturer’s instructions. Cells were then resuspended in 1X Perm/Wash buffer (BD Biosciences) and 
incubated for 20 min with polyclonal rabbit antibodies against mouse S100A8 or S100A9 (Vogl et al., 2014). After 
washing, cells were incubated for 20 min with Pacific Orange-labelled goat anti-rabbit secondary antibody (Life 
Technologies) diluted in 1X Perm/Wash buffer, washed and resuspended in PBS+0.5%FBS and analyzed by FACS. 
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To analyze the concentration of S100A8/9 in the plasma, peripheral blood was collected in Microtainer PST tube (BD) 
and centrifuged to collect the plasma fraction. Samples were stored at -80°C until the moment of analysis. S100A8/9 was 
quantified by ELISA as previously described (Vogl et al., 2014). 
Immunohistochemical staining of low-risk MDS and age-matched controls (biopsies obtained for disease staging from 
lymphoma patients without evidence of intramedullary localization) were performed on 5 µm bone marrow sections, 
which were deparaffinized in xylene and hydrated in a graded series of alcohol. Antigen retrieval was achieved by 
microwave treatment in citrate buffer (10mM pH 6.0) and blocking of the endogenous peroxidases was performed with 
3% H2O2 in PBS. Sections were blocked using 10% normal human and goat serum (DAKO) in Teng-T solution followed 
by overnight incubation at 4°C with primary antibody anti-S100A8 and S100A9 (Vogl et al., 2014) diluted 1:500, CD271 
(Sigma Aldrich) diluted 1:200, or normal rabbit immunoglobulin (DAKO) diluted accordingly. Immunoreactions were 
detected using biotinylated secondary antibody (goat anti-rabbit, 1:2000 dilution) with Vectastain ABC Elite Kit (Vector 
Laboratories) and 3,3’-diaminobenzidine tetrahydrochloride (Sigma Aldrich). For all stainings, nuclei were 
counterstained with haematoxylin (Vector Laboratories). Images of the stained tissue were acquired using a Leica 
DM5500B upright microscope with 40x lenses and LAS-AF image acquisition software.  
Sbds-knockdown and expression analysis in OP9 cells 
OP9 cells were grown in DMEM+10%FBS+1%PenStrep. Sbds RNA interference was achieved by lentiviral transduction. 
Briefly, short hairpin RNAs against Sbds (shSbds1:TRCN0000108586; and shSbds4:TRCN0000316346) and a 
commercial non-target control (shControl: SHC002 [SHC]), cloned in the pLKO.1 backbones, were selected from the 
Mission TRC shRNA library (Sigma-Aldrich). Lentiviral shRNAs were produced in HEK293T cells after cotransfection 
of shControl, shSbds1, or shSbds4 together with the packaging plasmids pSPAX2 and pMDG.2. OP9 cells were infected 
with lentivirus for 72 hours in the presence of 4 µg/mL polybrene and selected 72hours with 2 µg/mL puromycin. 
RNA isolation, conversion to cDNA and qPCR were performed accordingly to previously described methods (Zambetti 
et al., 2015), using the SuperScript II Reverse Transcriptase (Thermo Fisher Scientific) for conversion to cDNA. For 
qPCR, expression levels were obtained using the ddCt method using GAPDH as internal control and shControl sample 
as calibrator. The following primers were used: Sbds-Fw: GCGCTTCGAAATCGCCTG; Sbds-Rv: 
TCTGGTCGTCTGTCCCAAATG; S100a8-Fw: ATCACCATGCCCTCTACAAGAATG; S100a8-Rv: 
GTCCAATTCTCTGAACAAGTTTTCG; S100a9-Fw: AAGCTGCATGAGAACAACCCA; S100a9-Rv: 
CCCAGAACAAAGGCCATTGA; Cdkn1a-Fw: CCTGGTGATGTCCGACCTG; Cdkn1a-Rv: 
CCATGAGCGCATCGCAATC; Bax-Fw: CCGGCGAATTGGAGATGAACT; Bax-Rv: 
CCAGCCCATGATGGTTCTGAT. 
For protein analysis, cells were lysed in Carin lysis buffer (20 mM Tris-HCl pH 8.0, 138 mM NaCl, 10mM EDTA, 100 
mM NaF, 1% NP-40, 10% glycerol, 2mM sodium vanadate) supplemented with 0.5 mM DTT and the protease inhibitor 
SigmaFast (Sigma Aldrich). 32 µg of protein per condition were denatured and separated on a Novex NuPage 4-12% Bis-
Tris Gradient gel (Life Technologies) and transferred to Protran BA83 blotting paper (GE Healthcare Sciences). After 
blocking, membranes were incubated overnight at 4°C with the following primary antibodies: goat polyclonal anti-SBDS 
(Santa Cruz, S-15, 1:200); rabbit polyclonal anti- p53 (Leica, CM5, 1:2000). Beta-actin was used as a loading control 
(mouse monoclonal anti-beta-actin, clone AC-15, Sigma-Aldrich, 1:10,000 dilution). After washing, blots were incubated 
with the following secondary antibody: IRDye 800CW Donkey anti-Goat IgG (H + L), IRDye® 800CW Donkey anti-
Rabbit IgG (H + L), and IRDye 800CW Donkey anti-mouse IgG (H + L) (all from Li-COR and diluted 1:10,000). After 
final washing steps, Western blots were scanned and processed using an Odyssey Infrared Imager (Li-COR Biosciences). 
HSPCs in vitro culture, S100A8/A9 exposure and CFU-C assay 
LKS and Lin- c-Kit+ Sca-1- cells were sorted from wild type C57BL/6 mice and cultured in a serum-free medium, with 
the following composition: X-Vivo 15 (Lonza), 1% detoxified BSA, 50 μM β-mercaptoethanol (Life Technologies), 1:100 
GlutaMAX™ Supplement (Life Technologies), 20 ng/ml recombinant murine SCF (Peprotech), 100 ng/ml recombinant 
murine Flt3-Ligand (Peprotech), 1:100 penicillin-streptomycin mixture (Life Technologies). The medium was 
supplemented with recombinant murine S100A8/9, produced with the same methods described earlier (Vogl et al., 2006), 
at a final, clinically relevant concentration of 25-50 μg/ml, in the range of concentrations measured in the bone marrow 
supernatants of MDS patients (List, 2014). A heat-inactivated control was obtained by incubating S100A8/9 at 80°C for 
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30 min; the protein was cooled-down and next added to the HSPC medium with the same concentration and volume as 
S100A8/9. LKS and Lin- c-Kit+ Sca-1- cells were cultured in 96-well plates at a cell density of 2.5x104 cells/well. 
For human studies, cryopreserved CD34+ cells were used, which were isolated from cord blood obtained under informed 
consent by Ficoll gradient and MACS separation (Miltenyi Biotec). Thawed cells were resuspended in StemSpan SFEM 
II (STEMCELL Technologies) and recombinant human S100A8/9 was added (R&D systems) at a final concentration of 
50 μg/ml. For the control medium, an equal volume of vehicle (PBS) was added. Cells were seeded in flat bottom 96 
well-plates (5x104 cells/well). 
For both mouse and human studies, cells were harvested at 4h for γH2AX and cell cycle studies and at 24 h for apoptosis 
assay. 
To assess the effect of S100A9 on HSPC function, CD34+ cord blood cells were resuspended in SFEM1 medium (Stemcell 
Technologies) containing SCF (50 ng/ml) and human recombinant S100A9 (2.5 μg/ml,ProSpec) or PBS control and 
seeded in 96-well plates (2x104 cells/well). After one week of preconditioning (37ºC, 5% CO2), cells were pooled. 2,000 
cells per condition were resuspended in 400 µl IMDM and transferred to 3.6 ml of MethoCult H84434 (Stemcell 
Technologies). Cells were plated in triplicate on 1 cm² petri-dishes (1 ml/dish) and incubated at 37ºC/5% CO2. Colonies 
were counted after 12-14 days.  
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